Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olena Barbash

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Cancer Immunology Research|February 19, 2022
Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell-Mediated Antitumor Immune ResponsesAndrew Fedoriw, Leilei Shi, Shane O'Brien, et al.
Nature|May 23, 2014
SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancerPawel K Mazur, Nicolas Reynoird, Purvesh Khatri, et al.
Oncogenesis|April 21, 2018
MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancersAnastasia Wyce, Jeanne J Matteo, Shawn W Foley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2023
A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast CancerDavid W Cescon, John Hilton, Serafin Morales Murilo, et al.
Plos One|September 7, 2013
BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor modelsAnastasia Wyce, Gopinath Ganji, Kimberly N Smitheman, et al.
Nature Communications|September 27, 2022
TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphomaTatiana Erazo, Chiara M Evans, Daniel Zakheim, et al.
The Oncologist|March 11, 2022
Homologous Recombination Deficiency: Concepts, Definitions, and AssaysMark D Stewart, Diana Merino Vega, Rebecca C Arend, et al.
Blood|December 17, 2013
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762Aristeidis Chaidos, Valentina Caputo, Katerina Gouvedenou, et al.
JNCI Cancer Spectrum|April 25, 2020
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid TumorsSarina A Piha-Paul, Christine L Hann, Christopher A French, et al.
Blood|December 9, 2024
Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivationViral Shah, George Giotopoulos, Hikari Osaki, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Cancer Immunology Research|February 19, 2022
Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell-Mediated Antitumor Immune ResponsesAndrew Fedoriw, Leilei Shi, Shane O'Brien, et al.
Nature|May 23, 2014
SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancerPawel K Mazur, Nicolas Reynoird, Purvesh Khatri, et al.
Oncogenesis|April 21, 2018
MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancersAnastasia Wyce, Jeanne J Matteo, Shawn W Foley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2023
A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast CancerDavid W Cescon, John Hilton, Serafin Morales Murilo, et al.
Plos One|September 7, 2013
BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor modelsAnastasia Wyce, Gopinath Ganji, Kimberly N Smitheman, et al.
Nature Communications|September 27, 2022
TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphomaTatiana Erazo, Chiara M Evans, Daniel Zakheim, et al.
The Oncologist|March 11, 2022
Homologous Recombination Deficiency: Concepts, Definitions, and AssaysMark D Stewart, Diana Merino Vega, Rebecca C Arend, et al.
Blood|December 17, 2013
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762Aristeidis Chaidos, Valentina Caputo, Katerina Gouvedenou, et al.
JNCI Cancer Spectrum|April 25, 2020
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid TumorsSarina A Piha-Paul, Christine L Hann, Christopher A French, et al.
Blood|December 9, 2024
Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivationViral Shah, George Giotopoulos, Hikari Osaki, et al.
Pageof 4